Julie Cherrington

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Living Beings

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
O'Farrell A Marie; van Vliet Andre; Abou Farha Khalid; Cherrington Julie M; Campbell David A; Li Xinqiang; Hanway Denise; Li Jianke; Guler Hans-Peter
Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
Schittenhelm M M; Yee K W H; Tyner J W; McGreevey L; Haley A D; Town A; Griffith D J; Bainbridge T; Braziel R M; O'Farrell A-M; Cherrington J M; Heinrich M C
FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248).
Patyna Shem; Laird A Douglas; Mendel Dirk B; O'farrell Anne-Marie; Liang Chris; Guan Huiping; Vojkovsky Tomas; Vasile Stefan; Wang Xueyan; Chen Jeffrey; Grazzini Maren; Yang Cheng Y; Haznedar Joshua O; Sukbuntherng Juthamas; Zhong Wei-Zhu; Cherrington Julie M; Hu-Lowe Dana
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Julie Cherrington (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2007: O'Farrell A Marie; van Vliet Andre; Abou Farha Khalid; Cherrington Julie M; Campbell David A; Li Xinqiang; Hanway Denise; Li Jianke; Guler Hans-Peter
Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
Clinical therapeutics 2007;29(8):1692-705.
2006: Schittenhelm M M; Yee K W H; Tyner J W; McGreevey L; Haley A D; Town A; Griffith D J; Bainbridge T; Braziel R M; O'Farrell A-M; Cherrington J M; Heinrich M C
FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(11):2008-14.
2006: Patyna Shem; Laird A Douglas; Mendel Dirk B; O'farrell Anne-Marie; Liang Chris; Guan Huiping; Vojkovsky Tomas; Vasile Stefan; Wang Xueyan; Chen Jeffrey; Grazzini Maren; Yang Cheng Y; Haznedar Joshua O; Sukbuntherng Juthamas; Zhong Wei-Zhu; Cherrington Julie M; Hu-Lowe Dana
SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.
Molecular cancer therapeutics 2006;5(7):1774-82.
2006: Potapova Olga; Laird A Douglas; Nannini Michelle A; Barone Angela; Li Guangmin; Moss Katherine G; Cherrington Julie M; Mendel Dirk B
Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.
Molecular cancer therapeutics 2006;5(5):1280-9.
2005: Fiedler Walter; Serve Hubert; Döhner Hartmut; Schwittay Michael; Ottmann Oliver G; O'Farrell Anne-Marie; Bello Carlo L; Allred Randy; Manning William C; Cherrington Julie M; Louie Sharianne G; Hong Weiru; Brega Nicoletta M; Massimini Giorgio; Scigalla Paul; Berdel Wolfgang E; Hossfeld Dieter K
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.
Blood 2005;105(3):986-93.
2004: Yee Kevin W H; Schittenhelm Marcus; O'Farrell Anne-Marie; Town Ajia R; McGreevey Laura; Bainbridge Troy; Cherrington Julie M; Heinrich Michael C
Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.
Blood 2004;104(13):4202-9.
2004: O'Farrell Anne-Marie; Yuen Helene A; Smolich Beverly; Hannah Alison L; Louie Sharianne G; Hong Weiru; Stopeck Alison T; Silverman Lewis R; Lancet Jeffrey E; Karp Judith E; Albitar Maher; Cherrington Julie M; Giles Francis J
Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
Leukemia research 2004;28(7):679-89.
2004: Morimoto Alyssa M; Tan Nguyen; West Kristina; McArthur Grant; Toner Guy C; Manning William C; Smolich Beverly D; Cherrington Julie M
Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor.
Oncogene 2004;23(8):1618-26.
2004: Zangari Maurizio; Anaissie Elias; Stopeck Alison; Morimoto Alyssa; Tan Nguyen; Lancet Jeffrey; Cooper Maureen; Hannah Alison; Garcia-Manero Guillermo; Faderl Stephan; Kantarjian Hagop; Cherrington Julie; Albitar Maher; Giles Francis J
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 1):88-95.
2003: Pryer Nancy K; Lee Leslie B; Zadovaskaya Regina; Yu Xiaoming; Sukbuntherng Juthamas; Cherrington Julie M; London Cheryl A
Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(15):5729-34.
2003: O'Farrell Anne-Marie; Foran James M; Fiedler Walter; Serve Hubert; Paquette Ron L; Cooper Maureen A; Yuen Helene A; Louie Sharianne G; Kim Heidi; Nicholas Susan; Heinrich Michael C; Berdel Wolfgang E; Bello Carlo; Jacobs Mark; Scigalla Paul; Manning William C; Kelsey Stephen; Cherrington Julie M
An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(15):5465-76.
2003: Christensen James G; Schreck Randall; Burrows Jon; Kuruganti Poonam; Chan Emily; Le Phuong; Chen Jeffrey; Wang Xueyan; Ruslim Lany; Blake Robert; Lipson Kenneth E; Ramphal John; Do Steven; Cui Jingrong J; Cherrington Julie M; Mendel Dirk B
A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.
Cancer research 2003;63(21):7345-55.
2003: Moss Katherine G; Toner Guy C; Cherrington Julie M; Mendel Dirk B; Laird A Douglas
Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans.
The Journal of pharmacology and experimental therapeutics 2003;307(2):476-80.
2003: Abrams Tinya J; Murray Lesley J; Pesenti Enrico; Holway Vicky Walker; Colombo Tina; Lee Leslie B; Cherrington Julie M; Pryer Nancy K
Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.
Molecular cancer therapeutics 2003;2(10):1011-21.
2003: Giles Francis J; Stopeck Alison T; Silverman Lewis R; Lancet Jeffrey E; Cooper Maureen A; Hannah Alison L; Cherrington Julie M; O'Farrell Anne-Marie; Yuen Helene A; Louie Sharianne G; Hong Weiru; Cortes Jorge E; Verstovsek Srdan; Albitar Maher; O'Brien Susan M; Kantarjian Hagop M; Karp Judith E
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Blood 2003;102(3):795-801.
2003: London Cheryl A; Hannah Alison L; Zadovoskaya Regina; Chien May B; Kollias-Baker Cynthia; Rosenberg Mona; Downing Sue; Post Gerald; Boucher Joseph; Shenoy Narmada; Mendel Dirk B; McMahon Gerald; Cherrington Julie M
Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2755-68.
2003: Abrams Tinya J; Lee Leslie B; Murray Lesley J; Pryer Nancy K; Cherrington Julie M
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
Molecular cancer therapeutics 2003;2(5):471-8.
2003: Laird A Douglas; Li Guangmin; Moss Katherine G; Blake Robert A; Broome Martin A; Cherrington Julie M; Mendel Dirk B
Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells.
Molecular cancer therapeutics 2003;2(5):461-9.
2003: O'Farrell Anne-Marie; Abrams Tinya J; Yuen Helene A; Ngai Theresa J; Louie Sharianne G; Yee Kevin W H; Wong Lily M; Hong Weiru; Lee Leslie B; Town Ajia; Smolich Beverly D; Manning William C; Murray Lesley J; Heinrich Michael C; Cherrington Julie M
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
Blood 2003;101(9):3597-605.
2003: Giles Francis J; Cooper Maureen A; Silverman Lewis; Karp Judith E; Lancet Jeffrey E; Zangari Maurizio; Shami Paul J; Khan Khuda D; Hannah Alison L; Cherrington Julie M; Thomas Deborah A; Garcia-Manero Guillermo; Albitar Maher; Kantarjian Hagop M; Stopeck Alison T
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
Cancer 2003;97(8):1920-8.
2003: DePrimo Samuel E; Wong Lily M; Khatry Deepak B; Nicholas Susan L; Manning William C; Smolich Beverly D; O'Farrell Anne-Marie; Cherrington Julie M
Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification.
BMC cancer 2003;3():3.
2003: Mendel Dirk B; Laird A Douglas; Xin Xiaohua; Louie Sharianne G; Christensen James G; Li Guangmin; Schreck Randall E; Abrams Tinya J; Ngai Theresa J; Lee Leslie B; Murray Lesley J; Carver Jeremy; Chan Emily; Moss Katherine G; Haznedar Joshua O; Sukbuntherng Juthamas; Blake Robert A; Sun Li; Tang Cho; Miller Todd; Shirazian Sheri; McMahon Gerald; Cherrington Julie M
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):327-37.
2003: Laird A Douglas; Cherrington Julie M
Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents.
Expert opinion on investigational drugs 2003;12(1):51-64.
2003: Murray Lesley J; Abrams Tinya J; Long Kelly R; Ngai Theresa J; Olson Lisa M; Hong Weiru; Keast Paul K; Brassard Jacqueline A; O'Farrell Anne Marie; Cherrington Julie M; Pryer Nancy K
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.
Clinical & experimental metastasis 2003;20(8):757-66.
2002: Yee Kevin W H; O'Farrell Anne Marie; Smolich Beverly D; Cherrington Julie M; McMahon Gerald; Wait Cecily L; McGreevey Laura S; Griffith Diana J; Heinrich Michael C
SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.
Blood 2002;100(8):2941-9.
2002: Liao Albert T; Chien May B; Shenoy Narmada; Mendel Dirk B; McMahon Gerald; Cherrington Julie M; London Cheryl A
Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.
Blood 2002;100(2):585-93.
2002: Zhang Qingling; Pang Wyming Lee; Chen Hui; Cherrington Julie; Lipson Kenneth; Antonian Lida; Shawver Laura K
Application of LC/MS/MS in the quantitation of SU101 and SU0020 uptake by 3T3/PDGFr cells.
Journal of pharmaceutical and biomedical analysis 2002;28(3-4):701-9.
2002: Laird A Douglas; Christensen Jmes G; Li Guangmin; Carver Jeremy; Smith Kimberly; Xin Xiaohua; Moss Katherine G; Louie Sharianne G; Mendel Dirk B; Cherrington Julie M
SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2002;16(7):681-90.
2001: Christensen J G; Schreck R E; Chan E; Wang X; Yang C; Liu L; Cui J; Sun L; Wei J; Cherrington J M; Mendel D B
High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12):4230-8.
2001: Miller M D; Margot N A; Lamy P D; Fuller M D; Anton K E; Mulato A S; Cherrington J M
Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.
Journal of acquired immune deficiency syndromes (1999) 2001;27(5):450-8.
2001: Smolich B D; Yuen H A; West K A; Giles F J; Albitar M; Cherrington J M
The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts.
Blood 2001;97(5):1413-21.
2000: Mendel D B; Schreck R E; West D C; Li G; Strawn L M; Tanciongco S S; Vasile S; Shawver L K; Cherrington J M
The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(12):4848-58.
2000: Strawn L M; Kabbinavar F; Schwartz D P; Mann E; Shawver L K; Slamon D J; Cherrington J M
Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(7):2931-40.
2000: Mendel D B; Laird A D; Smolich B D; Blake R A; Liang C; Hannah A L; Shaheen R M; Ellis L M; Weitman S; Shawver L K; Cherrington J M
Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.
Anti-cancer drug design 2000;15(1):29-41.
2000: Van Rompay K K; Miller M D; Marthas M L; Margot N A; Dailey P J; Canfield D R; Tarara R P; Cherrington J M; Aguirre N L; Bischofberger N; Pedersen N C
Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA.
Journal of virology 2000;74(4):1767-74.
2000: Cherrington J M; Strawn L M; Shawver L K
New paradigms for the treatment of cancer: the role of anti-angiogenesis agents.
Advances in cancer research 2000;79():1-38.
1999: Bowen E F; Cherrington J M; Lamy P D; Griffiths P D; Johnson M A; Emery V C
Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy.
Journal of medical virology 1999;58(4):402-7.
1999: Van Rompay K K; Cherrington J M; Marthas M L; Lamy P D; Dailey P J; Canfield D R; Tarara R P; Bischofberger N; Pedersen N C
9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA.
Antimicrobial agents and chemotherapy 1999;43(4):802-12.
1999: van Rompay K K; Dailey P J; Tarara R P; Canfield D R; Aguirre N L; Cherrington J M; Lamy P D; Bischofberger N; Pedersen N C; Marthas M L
Early short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine treatment favorably alters the subsequent disease course in simian immunodeficiency virus-infected newborn Rhesus macaques.
Journal of virology 1999;73(4):2947-55.
1999: Jacobson M A; Wilson S; Stanley H; Holtzer C; Cherrington J; Safrin S
Phase I study of combination therapy with intravenous cidofovir and oral ganciclovir for cytomegalovirus retinitis in patients with AIDS.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999;28(3):528-33.
1999: Miller M D; Anton K E; Mulato A S; Lamy P D; Cherrington J M
Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro.
The Journal of infectious diseases 1999;179(1):92-100.
1999: Wainberg M A; Miller M D; Quan Y; Salomon H; Mulato A S; Lamy P D; Margot N A; Anton K E; Cherrington J M
In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA.
Antiviral therapy 1999;4(2):87-94.
1999: Safrin S; Cherrington J; Jaffe H S
Cidofovir. Review of current and potential clinical uses.
Advances in experimental medicine and biology 1999;458():111-20.
1998: Cherrington J M; Fuller M D; Lamy P D; Miner R; Lalezari J P; Nuessle S; Drew W L
In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcome.
The Journal of infectious diseases 1998;178(6):1821-5.
1998: Cihlar T; Fuller M D; Mulato A S; Cherrington J M
A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture.
Virology 1998;248(2):382-93.
1998: Miller M D; Lamy P D; Fuller M D; Mulato A S; Margot N A; Cihlar T; Cherrington J M
Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity.
Molecular pharmacology 1998;54(2):291-7.
1998: Mulato A S; Lamy P D; Miller M D; Li W X; Anton K E; Hellmann N S; Cherrington J M
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy.
Antimicrobial agents and chemotherapy 1998;42(7):1620-8.
1998: Cihlar T; Fuller M D; Cherrington J M
Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments.
Journal of virology 1998;72(7):5927-36.
1997: Deeks S G; Collier A; Lalezari J; Pavia A; Rodrigue D; Drew W L; Toole J; Jaffe H S; Mulato A S; Lamy P D; Li W; Cherrington J M; Hellmann N; Kahn J
The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial.
The Journal of infectious diseases 1997;176(6):1517-23.
1997: Xiong X; Flores C; Fuller M D; Mendel D B; Mulato A S; Moon K; Chen M S; Cherrington J M
In vitro characterization of the anti-human cytomegalovirus activity of PMEA (Adefovir).
Antiviral research 1997;36(2):131-7.
1997: Mulato A S; Cherrington J M
Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses.
Antiviral research 1997;36(2):91-7.
1997: Cihlar T; Fuller M D; Cherrington J M
Expression of the catalytic subunit (UL54) and the accessory protein (UL44) of human cytomegalovirus DNA polymerase in a coupled in vitro transcription/translation system.
Protein expression and purification 1997;11(2):209-18.
1997: Smith I L; Cherrington J M; Jiles R E; Fuller M D; Freeman W R; Spector S A
High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes.
The Journal of infectious diseases 1997;176(1):69-77.
1996: Van Rompay K K; Cherrington J M; Marthas M L; Berardi C J; Mulato A S; Spinner A; Tarara R P; Canfield D R; Telm S; Bischofberger N; Pedersen N C
9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques.
Antimicrobial agents and chemotherapy 1996;40(11):2586-91.
1996: Foli A; Sogocio K M; Anderson B; Kavlick M; Saville M W; Wainberg M A; Gu Z; Cherrington J M; Mitsuya H; Yarchoan R
In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA).
Antiviral research 1996;32(2):91-8.
1996: Cherrington J M; Mulato A S; Fuller M D; Chen M S
Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro.
Antimicrobial agents and chemotherapy 1996;40(9):2212-6.
1996: Kim C U; McGee L R; Krawczyk S H; Harwood E; Harada Y; Swaminathan S; Bischofberger N; Chen M S; Cherrington J M; Xiong S F; Griffin L; Cundy K C; Lee A; Yu B; Gulnik S; Erickson J W
New series of potent, orally bioavailable, non-peptidic cyclic sulfones as HIV-1 protease inhibitors.
Journal of medicinal chemistry 1996;39(18):3431-4.
1996: Cherrington J M; Fuller M D; Mulato A S; Allen S J; Kunder S C; Ussery M A; Lesnikowski Z; Schinazi R F; Sommadossi J P; Chen M S
Comparative kinetic analyses of interaction of inhibitors with Rauscher murine leukemia virus and human immunodeficiency virus reverse transcriptases.
Antimicrobial agents and chemotherapy 1996;40(5):1270-3.
1996: Cherrington J M; Miner R; Hitchcock M J; Lalezari J P; Drew W L
Susceptibility of human cytomegalovirus to cidofovir is unchanged after limited in vivo exposure to various regimens of drug.
The Journal of infectious diseases 1996;173(4):987-92.
1995: Gu Z; Salomon H; Cherrington J M; Mulato A S; Chen M S; Yarchoan R; Foli A; Sogocio K M; Wainberg M A
K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine.
Antimicrobial agents and chemotherapy 1995;39(8):1888-91.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Julie Cherrington

Research Profile (preview)

Chemicals & Drugs

Living Beings

Anatomy

Phenomena

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Julie Cherrington (preview)

All Publications